Skip to main content
. 2022 Dec 5;209:105481. doi: 10.1016/j.antiviral.2022.105481

Table 1.

Inhibitory potencya of 24 primary hits against pseudovirus infection identified in the US FDA-approved drug library screening and their pharmacological target molecules.

Compound Target rVSVΔG-GFP/SARS2-S
rVSVΔG-GFP/VSVG
GFP (%) Hoechst (%) GFP (%) Hoechst (%)
Bazedoxifene acetate NR3A (ESR) 12.26 88.96 115.01 102.51
Toremifene NR3A (ESR)
IGF1R (CD221)
21.77 101.27 142.24 90.44
Tamoxifen citrate NR3A (ESR) 16.27 99.67 105.72 97.14
Toremifene citrate NR3A (ESR)
IGF1R (CD221)
8.32 99.98 109.35 98.74
Raloxifene hydrochloride NR3A (ESR) 9.66 101.70 97.55 103.53
Vandetanib (ZD6474) VEGFR2
EGFR
RET
20.29 104.11 107.38 99.04
AZD-9291 mesylate EGFR 5.36 98.67 112.06 98.67
Prochlorperazine Maleate DRD2 16.56 97.05 131.30 93.26
Thioridazine hydrochloride DRD2 15.80 98.59 118.64 95.38
Fluphenazine hydrochloride DRD2 19.31 103.35 106.20 100.59
Perphenazine DRD2 17.90 104.54 113.49 86.64
Trifluoperazine dihydrochloride DRD2 8.63 107.56 129.52 97.29
Chlorpromazine hydrochloride HTR2
HRH1
ADRA2
DRD2
CHRM
24.88 98.41 95.70 97.98
Asenapine Maleate HTR1A
HTR2A
HTR2C
HTR6
HTR7
DRD2
14.81 98.20 150.43 95.98
Sertraline hydrochloride SLC6A4 (HTT) 15.85 101.27 104.62 97.33
Trimipramine maleate SLC6A2 (NAT1)
SLC6A4 (HTT)
23.16 103.55 90.44 99.90
Nortriptyline hydrochloride SLC6A2 (NAT1)
SLC6A4 (HTT)
17.44 81.23 91.71 76.77
Amoxapine SLC6A4 (HTT)
SLC6A2 (NAT1)
23.68 102.06 116.48 99.31
Paroxetine hydrochloride SLC6A4 (HTT) 21.00 102.73 112.39 98.03
Clemastine fumarate HRH1 12.46 106.94 104.53 101.47
Dronedarone hydrochloride CACNA1-L
KCND3
KCNH2
KCNQ1
KCNJ3
KCNJ5
KCNJ11
ADRA1
ADRB1
10.87 99.72 138.68 101.34
Azithromycin dihydrate 50 S ribosomal subunit 18.36 100.22 101.10 101.30
Cinacalcet hydrochloride CASR 23.68 97.33 131.09 95.94
Imatinib Mesylate (STI571) BCR-ABL
FIP1L1-PDGFRA
KIT (CD117)
20.79 96.53 103.15 94.49
a

The mean value of vehicle-treated cells was set to 100%.